Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alcediag is active in the Biotechnology & Pharmaceuticals technology area with a focused set of patent filings. The portfolio currently reports 1 pending office action, which suggests a narrow area of technical inquiry for the pending application. This work is handled by 1 distinct examiner within 1 distinct art unit, reflecting a localized prosecution effort that avoids the complexity of multi-examiner portfolios.
The busiest examiner for the portfolio is OLJUSKIN, TIMUR YURYEVICH, who is managing 1 pending office action. Because the portfolio involves only 1 distinct examiner, the progress of the company's pending intellectual property depends on the review process of this individual. Practitioners should tailor their responses to the specific scientific standards favored by OLJUSKIN, TIMUR YURYEVICH.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WISE, OLIVIA M. | 1 | 33.9% | +29.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774752 | DIFFERENTIAL DIAGNOSIS OF BIPOLAR DISORDER AND UNIPOLAR DEPRESSION BY BLOOD RNA EDITING BIOMARKERS | WISE, OLIVIA M. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774752 | DIFFERENTIAL DIAGNOSIS OF BIPOLAR DISORDER AND UNIPOLAR DEPRESSION BY BLOOD RNA EDITING BIOMARKERS | WISE, OLIVIA M. | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17774752 | DIFFERENTIAL DIAGNOSIS OF BIPOLAR DISORDER AND UNIPOLAR DEPRESSION BY BLOOD RNA EDITING BIOMARKERS | WISE, OLIVIA M. | 1685 | §101§112 | Non-Final OA | — | Pending | May 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial